The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.
 
Nai-Jung Chiang
Honoraria - Ono Pharmaceutical; Roche
Research Funding - ACT Genomics; TTY Biopharm
 
Yan-Shen Shan
No Relationships to Disclose
 
Li-Yuan Bai
Honoraria - Lilly; Pfizer; SynCoreBio
Consulting or Advisory Role - Bristol-Myers Squibb
 
Chung-Pin Li
No Relationships to Disclose
 
Jen-Shi Chen
Research Funding - Astellas Pharma; AstraZeneca; Debiopharm Group; Janssen; Lilly; Merck KGaA; MSD Oncology; Ono Pharmaceutical; Roche; Senhwa Biosciences; SynCoreBio; TTY Biopharm
 
Shih-Hung Yang
Research Funding - ACT Genomics; Ono Pharmaceutical; TTY Biopharm
Travel, Accommodations, Expenses - PharmaEngine
 
Yung-Chia Kuo
No Relationships to Disclose
 
Yee Chao
No Relationships to Disclose
 
Yao-yu Hsieh
Honoraria - Lilly; Merck Serono; MSD; Roche
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Lilly; Merck; MSD; Novartis; Roche
 
Hsiang-fong Kao
Honoraria - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Roche
Consulting or Advisory Role - Novartis
Speakers' Bureau - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Ono Pharmaceutical; Roche
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Ono Pharmaceutical
 
Chin-Fu Hsiao
No Relationships to Disclose
 
Li-Tzong Chen
Leadership - ScinoPharm
Honoraria - OBI Pharma; PharmaEngine; Taivex Therapeutics
Research Funding - ACT Genomics; Bristol-Myers Squibb; Merck Serono; Novartis; Pfizer; Polaris; SynCoreBio; TTY Biopharm
Patents, Royalties, Other Intellectual Property - anti-alpha enolase (ENO-1) monoclonal antibody/HuniLife